These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 27940005)

  • 1. Cardiotoxicity of capecitabine: Captions not to bin.
    De Gennaro L; Brunetti ND; Resta M; Rutigliano D; Tarantini L; Caldarola P
    Int J Cardiol; 2017 Feb; 229():6. PubMed ID: 27940005
    [No Abstract]   [Full Text] [Related]  

  • 2. Capecitabine cardiotoxicity: How to limit life-threatening events.
    Lestuzzi C; Berretta M; De Paoli A
    Int J Cardiol; 2017 Feb; 229():5. PubMed ID: 27940007
    [No Abstract]   [Full Text] [Related]  

  • 3. Rapidly developing heart failure from capecitabine cardiotoxicity: a case study.
    Ambesh P; Zivari K; Obiagwu C; Shetty V; Kamholz S; Hollander G; Shani J
    Br J Clin Pharmacol; 2018 Apr; 84(4):800-802. PubMed ID: 29336052
    [No Abstract]   [Full Text] [Related]  

  • 4. Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care.
    Meulendijks D; van Hasselt JGC; Huitema ADR; van Tinteren H; Deenen MJ; Beijnen JH; Cats A; Schellens JHM
    Eur J Cancer; 2016 Feb; 54():120-130. PubMed ID: 26761784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer.
    Polk A; Shahmarvand N; Vistisen K; Vaage-Nilsen M; Larsen FO; Schou M; Nielsen DL
    BMJ Open; 2016 Oct; 6(10):e012798. PubMed ID: 27798021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer.
    Dyhl-Polk A; Vaage-Nilsen M; Schou M; Vistisen KK; Lund CM; Kümler T; Appel JM; Nielsen DL
    Acta Oncol; 2020 Apr; 59(4):475-483. PubMed ID: 31931649
    [No Abstract]   [Full Text] [Related]  

  • 7. Rechallenging 5-Fluorouracil in a Patient With Capecitabine-Induced Ventricular Fibrillation.
    Lai S; Marshall JL; Morrissey RL
    Clin Colorectal Cancer; 2015 Sep; 14(3):198-201. PubMed ID: 25858685
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of advanced colorectal cancer in a patient with cardiotoxic reactions to 5-fluorouracil and capecitabine using suboptimal doses.
    Cioffi JH; Estes DJ; Florou V; Ardalan B
    BMJ Case Rep; 2017 Nov; 2017():. PubMed ID: 29183892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine-induced hyperglycemia without hyperlipidemia: a case report.
    Avishek A; Jayanthi M; Biswajit D
    Eur J Clin Pharmacol; 2017 Nov; 73(11):1519-1521. PubMed ID: 28752256
    [No Abstract]   [Full Text] [Related]  

  • 10. Capecitabine-induced myopericarditis - A case report and review of literature.
    Saunders S; Anwar M
    J Oncol Pharm Pract; 2019 Jun; 25(4):1006-1010. PubMed ID: 29783917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine in advanced hepatocellular carcinoma.
    Murer F; Pozzan C; Peserico G; Farinati F
    Dig Liver Dis; 2016 Oct; 48(10):1260-1. PubMed ID: 27476466
    [No Abstract]   [Full Text] [Related]  

  • 12. Capecitabine-induced eruptive acral hyperpigmentation: Clinical and dermoscopic evaluation of two cases.
    Peccerillo F; Pampena R; Giannetti L; Pellacani G; Longo C
    Dermatol Ther; 2019 May; 32(3):e12853. PubMed ID: 30748073
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful Capecitabine Desensitization for a Delayed-Type Hypersensitivity Reaction.
    Demir S; Olgac M; Saglam S; Gelincik A; Colakoglu B; Buyukozturk S
    J Investig Allergol Clin Immunol; 2016; 26(1):66-7. PubMed ID: 27012024
    [No Abstract]   [Full Text] [Related]  

  • 14. Association of serum folate level with toxicity of capecitabine in patients with colorectal cancers: a prospective cohort study.
    Chan SL; Ma BB; Chan AK
    Hong Kong Med J; 2018 Jun; 24 Suppl 3(3):29-31. PubMed ID: 29937443
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of pharmacogenetics in capecitabine efficacy and toxicity.
    Lam SW; Guchelaar HJ; Boven E
    Cancer Treat Rev; 2016 Nov; 50():9-22. PubMed ID: 27569869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nasolacrimal Duct Stenosis after Oral Capecitabine Administration.
    Jang Y; Kim N; Lee KW; Choung HK; Khwarg SI
    Korean J Ophthalmol; 2019 Feb; 33(1):95-96. PubMed ID: 30746917
    [No Abstract]   [Full Text] [Related]  

  • 17. Capecitabine-Induced Takotsubo Cardiomyopathy: A Case Report and Literature Review.
    Qasem A; Bin Abdulhak AA; Aly A; Moormeier J
    Am J Ther; 2016; 23(5):e1188-92. PubMed ID: 25549075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine cardiotoxicity--case reports and literature review.
    Manojlovic N; Babic D; Stojanovic S; Filipovic I; Radoje D
    Hepatogastroenterology; 2008; 55(85):1249-56. PubMed ID: 18795667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using pharmacogenetics to prevent severe adverse reactions to capecitabine.
    García-González X; López-Fernández LA
    Pharmacogenomics; 2017 Aug; 18(13):1199-1213. PubMed ID: 28746000
    [No Abstract]   [Full Text] [Related]  

  • 20. Effectiveness and Tolerability of Maintenance Capecitabine Administrated to Patients with Metastatic Pancreatic Cancer Treated with First-Line FOLFIRINOX.
    Reure J; Follana P; Gal J; Evesque L; Cavaglione G; Saint A; François E
    Oncology; 2016; 90(5):261-6. PubMed ID: 27097162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.